Search

Both the growth and survival of landscape plants are difficult due to the harsh natural conditions in coastal areas of southern China. Many plants suffer from symptoms of salt damage. Different from the damages by salt in the soil, the symptoms of windblown salt are damage to young shoots and leaves. Plants at the windward side are damaged more than the leeward side. These cha-racteristics imply that the damage is due to salt in aerosols instead of salt in the soil. To test this hypothesis, we measured plant growth, soil and climate factors in 24 frontline coastal counties and cities of China. The results showed that the first-line coastal plants showed strong symptoms of salt damage, especially in the Taiwan Strait area (85.4% belonged to desalinized soil), and that the damage level was highly correlated with wind speed. Our results confirmed that aerosol salt is the major cause of plant damage in the coastal areas of southern China. We constructed the first distribution map of salt damage along frontline coastal regions of southern China and proposed methods for diagnosing aerosol salt damage. Selecting and configuring aerosol salt-tolerant plants, greening engineering measures, and follow-up maintenance were suggested for improving the overall effect and level of landscaping in the coastal areas of southern China.

The prevalence of diseases caused by EV71 infection has become a serious public health problem in the Western Pacific region. Due to a lack of effective treatment options, controlling EV71 epidemics has mainly focused on the research and development (R&D) of EV71 vaccines. Thus far, five organizations have completed pre-clinical studies focused on the development of inactivated EV71 whole-virus vaccines, including vaccine strain screening, process optimization, safety and immunogenicity evaluation, and are in different stages of clinical trials. Among these organizations, three companies in Mainland China [Beijing Vigoo Biological Co., Ltd. (Vigoo), Sinovac Biotech Ltd. (Sinovac) and Institute of Medical Biology, Chinese Academy of Medical Science (CAMS)] have recently completed Phase III trials for the vaccines they developed. In addition, the other two vaccines, developed by National Health Research Institutes (NHRI) of Taiwan and Inviragen Pte., Ltd (Inviragen), of Singapore, have also completed Phase I clinical trials. Published clinical trial results indicate that the inactivated EV71 vaccines have good safety and immunogenicity in the target population (infants) and confer a relatively high rate of protection against EV71 infection-related diseases. The results of clinical trials suggest a promising future for the clinical use of EV71 vaccines. Here, we review and highlight the recent progress on the R&D of inactivated EV71 whole-virus vaccines.